DPP-4 Inhibitor with Biguanide (Fixed-Dose Combination)
Alogliptin with Metformin
Brand names: Vipdomet
Adult dose
Dose: 12.5 mg/850 mg or 12.5 mg/1000 mg twice daily
Route: Oral
Frequency: Twice daily with meals
Clinical pearls
- Fixed-dose combination improves adherence when both components are required
- Alogliptin (DPP-4 inhibitor) is weight-neutral and low hypoglycaemia risk when used without sulphonylurea/insulin
- NICE NG28 (Type 2 diabetes): DPP-4 inhibitors are second-line options
- Check eGFR before initiating and at least annually — adjust or stop if eGFR falls <45
- EXAMINE trial: alogliptin showed cardiovascular non-inferiority in high-risk T2DM patients
- Swallow whole with food to minimise GI side effects
Contraindications
- eGFR <45 mL/min/1.73 m² (metformin component — risk of lactic acidosis)
- Acute/chronic metabolic acidosis
- Hepatic impairment
- Alcohol misuse
- Iodinated contrast media — withhold metformin 48 hours before and after if eGFR 30–60
- Heart failure (acute or decompensated)
- Conditions predisposing to lactic acidosis
Side effects
- Gastrointestinal (nausea, diarrhoea, abdominal pain — metformin)
- Nasopharyngitis, upper respiratory tract infections (DPP-4 class effect)
- Pancreatitis (rare — DPP-4 class warning)
- Arthralgia (rare — DPP-4 class)
- Lactic acidosis (rare but serious — metformin)
Interactions
- Insulin/sulphonylureas — hypoglycaemia risk if combined; may need dose reduction of those agents
- Iodinated contrast — withhold metformin component as above
- Cimetidine — increases metformin levels via renal tubular secretion competition
- Alcohol — increases lactic acidosis risk with metformin
Monitoring
- HbA1c (target per NICE NG28: typically 48–53 mmol/mol)
- eGFR at baseline, 3–6 monthly, and if intercurrent illness
- LFTs at baseline
- Lipase if symptoms of pancreatitis develop
Reference: BNF; NICE NG28 (Type 2 diabetes in adults, 2022); EXAMINE trial (NEJM 2013); https://bnf.nice.org.uk/drugs/alogliptin-with-metformin/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016